Most Innovative New Product Finalist (6th October 2016)
Our technology has been elected as a finalist at the
2016 Most Innovative New Product Award, administered by CONNECT in San Diego, CA.
Microbiome R&D and Business Collaboration Forum (3-4 October 2016)
GlyConMedics CEO attended the 4th Microbiome Congress held in San Diego, CA.
Diabetes Innovation Challenge Semi-Finalist (16th August 2016)
Our technology has been elected as a semi-finalist at the Diabetes Innovation Challenge contest, administered by T1D Exchange and M2D2 Clinical, held at
University of Massachusetts, Boston.
Our first patent granted in China(16th March 2016)
Chinese Patent Office has granted our first patent.
Our first patent granted in USA (26th January 2016)
United States Patent and Trademark Office has granted our first patent.
Australia USA Business Week (16th - 26th Feb February 2016)
GlyConMedics CEO attended the inaugural Australia United State Business Week (AUSBW) that was held in six key cities across the United States – Boston,
Chicago, Houston, Los Angeles, New York and San Francisco.
23rd World Diabetes Congress (30th November - 04 December 2015)
GlyConMedics CEO attended world diabetes congress organized by the International Diabetes Federation held at Vancouver, British Columbia, Canada.
Clinical Trial Conduct (14th October 2015)
Company phase 2 clinical trial has been approved by a Human Research Ethics Committee in India.
Clinical Trial Conduct (4th December 2014)
Company phase 2 clinical trial has been approved by a Human Research Ethics Committee in Australia.
First Patent granted (27th October 2014)
IP Australia has granted our first patent.
Advisory and scientific Board (1st September 2014)
Professor Lesley Campbell has joined our scientific advisory board.
Advisory and scientific Board (28h August 2014)
Dr Ivan Rajkovic has joined our scientific advisory board.
Phase 2 Clinical Trials (16th June 2014)
We have initiated activities related to conduct of our proof of concept clinical trial.
Investment (4th June 2014)
We have secured our first round of family and friends Investments.
Our second Patent has entered the national phase (23th May 2014)
Second PCT patent (PCT/AU2012/001442) entitled “Improved Synergistic Anti-Diabetic Compositions”, entered national phase in major countries.
Advisory and scientific Board (20th May 2014)
Professor Anthony Barnett has joined our scientific advisory board.
Commercialisation Australia Grant (12th May 2014)
We have received our proof-of-concept grant from The Australian Government to further develop its product and services.
Australia Week In China (4th Apr 2014)
GlyConMedics CEO attends Australia Week in China 2014 Conference organized by AusTrade to initiate dialogues with Chinese entities.
Advisory and scientific Board (7th Dec 2013)
Professor C. Ronald Kahn Chief Academic Officer of Joslin Diabetes Center, Boston has joined our scientific advisory board.
OZ101 tablets (7th December 2013)
We have manufactured our first GMP tablet OZ101 to conduct our proof-of-concept clinical trial in Australia and India.
Acceptance of First Patent (17th June 2013)
First patent entitled “Anti-Diabetic Compositions and Methods” granted in Australia.
First patent entitled “Anti-Diabetic Compositions and Methods”, entered national phase in major countries.
GlyConMedics LLC Founded (8th Mar 2013)
GlyConMedics LLC has been founded by Dr Nick N Gorgani.